Program Purpose

November 3, 2011
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD

Understanding of tumor immunobiology has increased dramatically in recent years, leading to the successful development of new immune-based treatment options to improve cancer outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy was designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. The audience for this annual, one-day educational program included students, post-doctoral fellows, and technicians from academia and industry as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy.

Prominent investigators summarized central themes and recent research in tumor immunology and cancer immunotherapy, including innate immunity, dendritic cells, T cell differentiation and intracellular signaling, and the tumor microenvironment as well as recent advances in the clinical application of tumor antigens for immunization, co-inhibition / co-stimulation of immune cells, adoptive immunotherapy, and immune monitoring in clinical trials of cancer immunotherapies. These topics were addressed in a series of lectures by thought leaders in the field and through interactive question and answer discussions. 

Intended Audience
The target audience for this program was basic scientists and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students and post-doctoral fellows and allied health professionals.

Program Goals

• Provide a framework of basic immunology to facilitate understanding of more sophisticated principles of tumor immunology and immunotherapy
• Provide a common terminology and knowledge base for participants from many different areas
• Review the biology of innate immunity, dendritic cells, T cell differentiation and intracellular signaling, and the tumor microenvironment as related to recent advances in cancer immunotherapies
• Summarize the principles of and recent advances in the application of tumor antigens for immunization, co-inhibition / co-stimulation of immune cells, adoptive immunotherapy, and immune monitoring in clinical trials of cancer immunotherapies
• Provide the opportunity for dialogue and professional interactions that promote collaboration and scientific exchange

Expected Learner Outcomes
Upon completion of this meeting, participants will be able to:

• Understand the key principles of tumor immunology and immunotherapy
• Describe the role of innate immunity, T cell differentiation and signaling, and the tumor microenvironment in cancer immunotherapies
• Discuss recent research and clinical applications of tumor immunization, immune co-inhibition / co-stimulation, adoptive immunotherapy, and biomarkers
• Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

The Primer on Tumor Immunology and Cancer Immunotherapy is a non-accredited continuing medical education event. No credits are offered for physician participation in this educational program.